
Patients can receive their first and subsequent doses of ZARXIO at no cost
Commercial Co-Pay Program for ZARXIO
The Sandoz One Source Commercial Co-Pay Program for ZARXIO supports eligible,* commercially insured patients with their out-of-pocket co-pay costs for ZARXIO.

The ZARXIO Co-Pay Program in 3 simple steps



Support services to help your patients on their treatment journey
Helping patients stay the course on their treatment journey is important. With this in mind, we created our commercial co-pay program with its convenient, streamlined online enrollment to help them do just that. To assist patients further, Sandoz One Source also offers Patient Assistance.

The Sandoz Patient Assistance Program provides certain medicines for free to patients with demonstrated financial need. Your patient may be eligible if they are experiencing financial hardship, cannot afford the cost of treatment and have limited or no prescription coverage.

Click here for additional ZARXIO resources.
This website provides general information and is not intended to provide reimbursement or legal advice. Furthermore, it is not intended to increase or maximize payment by any payer. Because laws, regulations, and coverage policies are complex and updated frequently, you should check with your local Medicare carrier and payers often or go to www.cms.gov.
Nothing in the information provided shall be construed as a guarantee of Sandoz regarding levels of reimbursement, payment, or charge that reimbursement will be received. The ultimate responsibility for obtaining reimbursement lies with the physician, provider, or patient. Please consult with your counsel or reimbursement specialist for any practice-specific reimbursement or billing questions.
Learn about ZIEXTENZO (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz1
*Eligibility Requirements: Prescription must be for an approved indication. This program is not health insurance. This program is for insured patients only; cash-paying or uninsured patients are not eligible. Patients are not eligible if prescription for ZARXIO is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity plans that do not cover prescription drugs, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. Co-Pay Program may apply to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. Co-Pay Program may not be combined with any other rebate, coupon, or offer. Co-Pay Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.
G-CSF=granulocyte colony-stimulating factor.
Reference: 1. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.